PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2)

Clinical trials for PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2) explained in plain language.

Never miss a new study

Get alerted when new PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2) trials appear

Sign up with your email to follow new studies for PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Early trial tests new weapon against advanced cancers

Disease control Ongoing

This early-stage study is testing the safety of a new cancer drug called sacituzumab tirumotecan in Japanese patients. The drug is being given alone and in combination with an existing immunotherapy (pembrolizumab) to people with advanced solid tumors or a specific type of advanc…

Matched conditions: PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2)

Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2)

Get alerted when new PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2) trials appear

Early trial tests new weapon against advanced cancers